fluoxetine / Generic mfg. - LARVOL DELTA

Chronopharmacology and implications for the safety and efficacy of anticonvulsants, antipsychotics, and antidepressants: A systematic review. (PubMed, J Psychopharmacol) - "Current evidence provides preliminary support that circadian rhythm may differentially affect the pharmacology of select psychotropic agents. Whether the foregoing translates into clinically meaningful differences in efficacy, tolerability, and/or posology of the evaluated agents/classes requires systematic evaluation. Given that evidence is predominantly preclinical, further studies using clinically relevant repeated-dose regimens and disease-relevant animal models are required."

Journal • Review • CNS Disorders • Epilepsy

A Case of Esophagitis Dissecans Superficialis in a Patient With Crohn's Disease (ACG 2026) - "Case Description/ We report the case of a 27-year-old male diagnosed with ileocolonic and upper gastrointestinal Crohnâs Disease (CD) at age 22, treated with adalimumab since diagnosis...His medical history was also notable for a psoriasiform rash managed with topical corticosteroids and major depressive disorder managed with fluoxetine...The patient was started on an 8-week course of omeprazole twice daily, followed by once-daily dosing for an additional 4 weeks...Figure: Upper third of the esophagus demonstrating circumferential sloughing and peeling of the superficial esophageal mucosa consistent with esophagitis dissecans superficialis (EDS). Figure: Middle third of the esophagus demonstrating extensive mucosal desquamation with longitudinal strips of sloughed superficial mucosa consistent with esophagitis dissecans superficialis (EDS)."

Clinical • CNS Disorders • Crohn's disease • Depression • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Major Depressive Disorder

SSRI Use in Irritable Bowel Syndrome and Its Impact on Disease Outcomes: A Propensity-Matched Real-World Cohort Study (ACG 2026) - "Cohort 1 received an SSRI (sertraline, escitalopram, citalopram, fluoxetine, or paroxetine) within 1 year of diagnosis without concurrent TCA use. Post-matching cohorts were well-balanced (79.7% female, ~80% White). SSRI use was associated with lower functional symptom persistence (57.0% vs. 60.7%; RR 0.94, 95% CI 0.93-0.94; p< 0.001; median time-to-recurrence 589 vs."

Clinical • Real-world • Real-world evidence • CNS Disorders • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Mood Disorders • Ulcerative Colitis

A multi-omics approach reveals molecular alterations in the digestive gland of Mytilus galloprovincialis following fluoxetine exposure. (PubMed, Aquat Toxicol) - "Based on these findings, a putative Adverse Outcome Pathway (AOP) was proposed to link the molecular events identified in this study to individual effects previously reported in the literature. Overall, these findings highlight the value of multi-omics approaches for elucidating pharmaceutical effects in marine organisms and underscore the importance of integrating molecular data with organism-level observations to support AOP development."

Journal • Infectious Disease • Novel Coronavirus Disease

QTc changes and early major adverse cardiovascular events associated with antidepressant treatment for major depressive disorder in adults: individual participant data network meta-regression of double blind randomised trials. (PubMed, BMJ) - "The effect of specific antidepressants on QTc interval differed between adults with depression. No evidence associated antidepressant use with early MACE and non-suicidal sudden death. To support shared decision making and taking into account the trade-off between benefits and harms, individual modifiable and non-modifiable risk factors should be considered when choosing antidepressants."

Adverse events • Clinical • Journal • Cardiovascular • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Yale University | Trial completion date: Dec 2026 ➔ Sep 2027 | Trial primary completion date: Jun 2026 ➔ Sep 2027

Trial completion date • Trial primary completion date • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

A conserved conformation-dependent mechanism for the TREK two-pore domain potassium channel inhibitors carvedilol and fluphenazine. (PubMed, Mol Pharmacol) - "Modulation of these channels has been proposed for potential antiarrhythmic and antidepressant effects. This study defined the off-target molecular mechanism of action of the clinically used drugs carvedilol and fluphenazine on TREK channels and identify the TREK channel fenestration as a promiscuous binding site for inhibitory drugs."

Journal • CNS Disorders

Hippocampal miR-34a/SIRT1 and BDNF Responses Following Adolescent Stress: Differential Effects of Ketamine and Fluoxetine. (PubMed, Turk Psikiyatri Derg) - "Adolescent CUMS induces depression-like behaviors by affecting the hippocampal miR-34a/SIRT1/BDNF axis. While the antidepressant effects of fluoxetine are associated with this axis, ketamine may exert its behavioral effects through different and possibly extra-hippocampal mechanisms. miR-34a may serve as a potential biomarker for depression related to early life stress."

Journal • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Psychiatry • BDNF • MIR34A • NLRP3 • SIRT1

Effect of Yueju Pill on the Pharmacokinetics and Antidepressant Effect of Fluoxetine in Rats. (PubMed, Curr Drug Metab) - "YJW enhances the blood exposure of FLX by influencing pharmacokinetics and synergizes with FLX through multi-target mechanisms. The strategy of combining YJW with low-dose FLX not only enhances efficacy but also mitigates FLX-associated gastrointestinal adverse effects. It provides a basis for the combination of YJW and FLX, which highlights the gut-brain axis as a critical target for developing novel therapeutic strategies."

Journal • PK/PD data • Preclinical • CNS Disorders • Depression • Inflammation • Psychiatry • BDNF • IL1B • IL6 • TNFA

Fluoxetine enhances the retention of fear extinction in corticosterone-exposed male adolescent rats. (PubMed, Prog Neuropsychopharmacol Biol Psychiatry) - "In contrast, vehicle-exposed adolescent rats were unaffected by chronic fluoxetine exposure (Experiment 1). These findings add to the growing evidence that corticosterone exposure alters treatment responses during adolescence and, importantly, suggest that fluoxetine could be an effective treatment for adolescents exposed to high levels of stress-related hormones (at least in male rats)."

Journal • Preclinical

A randomized surgical window of opportunity study evaluating fluoxetine and temozolomide in recurrent high-grade glioma (SNO 2026) - No abstract available

Clinical • Brain Cancer • Glioma • High Grade Glioma • Solid Tumor

A randomized surgical window of opportunity study evaluating fluoxetine and temozolomide in recurrent high-grade glioma (EANO 2026) - P1 | "Together, these data suggest that fluoxetine is tolerable alongside TMZ and may play a previously unreported immunometabolic role in glioma. This effect may be of particular benefit in the post TMZ setting, where compensatory mechanisms include upregulation of CCL2 to recruit immunosuppressive tumor-associated macrophages. This work supports further studies, potentially using increased maintenance doses of fluoxetine alongside TMZ."

Clinical • Late-breaking abstract • Brain Cancer • Glioma • High Grade Glioma • Oncology • Solid Tumor • CCL2 • CSF1 • CXCL8 • CYP1B1 • LAMP1 • MGMT • NQO1 • TDO2 • TIPARP

Celecoxib Ameliorates Chronic Restraint Stress-Induced Depression-Like Behavior in Sprague-Dawley Rats. (PubMed, Neuropsychiatr Dis Treat) - "Male Sprague-Dawley rats were randomly assigned to a control group, chronic restraint stress (CRS) model group, CRS plus celecoxib group, or CRS plus fluoxetine group. Celecoxib was also associated with lower concentrations of IL-1β, IL-6, TNF-α, and corticosterone, reduced hippocampal IBA-1 immunoreactivity, and less pronounced histological and ultrastructural alterations. These findings indicate that celecoxib was associated with improved behavioral outcomes and reduced inflammatory, endocrine, histological, and ultrastructural alterations in CRS-exposed rats."

Journal • Preclinical • CNS Disorders • Depression • Inflammation • Major Depressive Disorder • Mood Disorders • Psychiatry • IL1B • IL6 • TNFA

Brazilian Psychiatric Association Guidelines for the Treatment of Eating Disorders. (PubMed, Braz J Psychiatry) - "BN is typically managed in an outpatient setting, focusing on structured nutritional care and CBT-based treatment, with pharmacotherapy adjunctive, preferably fluoxetine. BED is treated in an outpatient setting with structured care and CBT, with lisdexamfetamine as the preferred pharmacotherapy when needed. These guidelines represent a significant advancement in managing eating disorders in Brazil, providing a structured framework for clinical care while also supporting the development of future public mental health policies."

Journal • Anorexia • Binge Eating Disorder • Bulimia • CNS Disorders • Psychiatry

Acceptability and feasibility of the Ushirikiano treatment model for Kenyan adolescents: a pilot randomized controlled trial. (PubMed, Front Child Adolesc Psychiatry) - "We conducted a pilot randomized controlled trial to examine the acceptability, feasibility, and preliminary effectiveness of the Ushirikiano treatment model, a task-shifted, stepped-care approach combining a brief (four-session) group IPT-A (IPT-G-A) delivered by community health promoters, with fluoxetine for severe cases where indicated...These findings support further evaluation in fully powered trials to determine clinical effectiveness for CMDs, cost-effectiveness, and optimal implementation strategies. https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=33227, Pan African Clinical Trial Registry, PACTR202503728947243."

Clinical • Journal • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Psychiatry • Psychosomatic Disorders

Sishen wan modulates gut microbial and short-chain fatty-acid imbalances and ameliorates behavioral and inflammatory abnormalities in mice with chronic sleep deprivation. (PubMed, Front Microbiol) - "Male C57BL/6 J mice underwent CSD using a modified multiple-platform method and received three doses of SSW or fluoxetine...SSW alleviated CSD-associated behavioral abnormalities, tissue injury, and inflammation, with the high dose showing the most consistent effects. These improvements were accompanied by changes in gut microbial composition and SCFA profiles."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Transplantation

Modulation of the serotonergic system affects ventilation parameters and activity of respiratory nerves in a streptozotocin-induced Alzheimer's disease rat model. (ERS 2026) - "After 3 weeks, plethysmography experiments with fluoxetine (FLX, selective serotonin reuptake inhibitor) were conducted under conditions of normoxia, hypoxia and hypercapnia. Afterward, activity of hypoglossal and phrenic nerves was measured in anaesthetized rats during hypoxia before and after treatment with ondansetron (5-HT3 receptor antagonist)... Stimulation of the serotonergic system during hypoxia and hypercapnia, eliminates differences in minute ventilation between the study groups, suggesting its therapeutic potential. 5-HT3 receptor inhibition affected respiratory nerves activity only in STZ rats, which may be associated with an increased incidence of sleep apneas in AD. The study was funded by the National Science Centre 2022/45/B/00221."

Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Association of Gestational Maternal Medications and Microtia Incidence (AAO-HNSF 2026) - "Several opioids were positively associated with microtia, including morphine (1.35, 95% CI: 1.28-1.42) and hydromorphone (OR: 1.15, 95% CI: 1.06 – 1.24). Betamethasone (OR 1.63, 95% CI: 1.51-1.76), metoclopramide (OR: 1.25, 95% CI: 1.18-1.32), ondansetron (OR: 1.10, 95% CI: 1.03 – 1.17), gabapentin (OR: 1.23, 95% CI: 1.05 – 1.44) and nitrofuran derivatives (OR: 1.14, 95% CI: 1.05 – 1.23) were also associated with higher microtia incidence. Fluoxetine (OR: 0.66, 95% CI: 0.53 – 0.83), doxylamine (OR: 0.77, 95% CI: 0.70 – 0.85), lamotrigine (OR: 0.57, 95% CI: 0.39 – 0.83), hydrocodone (OR: 0.90, 95% CI: 0.85 – 0.96), oxycodone (OR: 0.90, 95% CI: 0.84 – 0.96), and fentanyl (OR: 0.78, 95% CI: 0.73 – 0.83) were associated with lower odds of microtia incidence... This analysis suggests several gestational medications associated with increased odds of microtia in patients. Further clinical investigation is warranted to differentiate between maternal conditions and environmental..."

Drugs for prevention of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Pharmacological insights into fluvoxamine maleate: σ1 receptor agonism, multimodal mechanisms, and therapeutic repositioning. (PubMed, Curr Opin Pharmacol) - "Fluvoxamine demonstrates one of the highest affinities for σ1R among SSRIs, exceeding those of sertraline and fluoxetine, via dissociating σ1R from BiP chaperones to improve protein refolding and cellular resilience. Preclinical experiments illustrate its inhibition of unfolded protein response indicators, reinstatement of glutamatergic transmission, and stimulation of parvalbumin interneurons, resulting in antipsychotic-like effects in schizophrenia and neuroprotection against ketamine-induced impairments...σ1R agonism is fundamental to its effectiveness in disorders caused by ER stress, such as schizophrenia and tardive dyskinesia, and in neuropsychiatric sequelae associated with protracted COVID. Clinical translation encounters obstacles in dose optimization and σ1R selectivity; yet, current studies highlight its multimodal efficacy in neurodegeneration, fibrosis, and psychopharmacology."

Journal • Review • CNS Disorders • Depression • Fibrosis • Immunology • Inflammation • Mood Disorders • Movement Disorders • Novel Coronavirus Disease • Obsessive-Compulsive Disorder • Psychiatry • Schizophrenia

Transcriptome-based classification in mice with ASD-risk mutations. (PubMed, Science) - "The two groups differed in sex bias, regional specificity, developmental stability, cell type remodeling, and responses to fluoxetine and lithium. Single-nucleus RNA-seq revealed broader cell type remodeling in group 1 than in group 2, and cell type-specific modules showed reciprocal associations that mirrored bulk transcriptomic signatures. The framework classifies independent mouse lines and identifies subgroups with conserved synaptic directionality, supporting molecular stratification."

Journal • Preclinical • Autism Spectrum Disorder • Genetic Disorders

Design of a sodium polyacrylate/carboxymethyl-chitosan-based imprinted cryogel for fluoxetine adsorption in continuous mode. (PubMed, Chemosphere) - "Fluoxetine (FLX) contamination in aquatic environments poses significant ecological risks, highlighting the need for efficient and selective removal technologies. Competitive adsorption with citalopram confirmed the selective recognition of FLX by MIC/NaPA-CMCs, yielding higher FLX uptake and a relative selectivity coefficient (K' > 1) than the non-imprinted cryogel. These results demonstrate the potential of the developed imprinted cryogel for selective FLX removal under continuous-flow conditions."

Journal

A Multicenter Clinical Study on Shuganjieyu Capsule Combined With Fluoxetine in the Treatment of Depression (clinicaltrials.gov) - P=N/A | N=160 | Completed | Sponsor: Peking University | Not yet recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Mood Disorders • Psychiatry

LYMPHODEP: Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants (clinicaltrials.gov) - P=N/A | N=50 | Completed | Sponsor: Germans Trias i Pujol Hospital | Trial completion date: Jul 2027 ➔ Jul 2026 | Trial primary completion date: Dec 2026 ➔ Jun 2026 | Not yet recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Inflammation • Mood Disorders • Psychiatry

Drug repurposing to combat viral infectious diseases: principles and illustration with Prozac® (PubMed, Med Sci (Paris)) - "This review presents three repurposing strategies, illustrated with therapeutic compounds notably fluoxetine (Prozac®), a selective serotonin reuptake inhibitor antidepressant that also exhibits several antiviral mechanisms of action. The examples discussed in this review highlight both the potential and the limitations of drug repurposing, particularly in a "plug-and-play" approach."

Journal • Review • Infectious Disease